⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 28, 2018Clinical Cancer Research

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

Sara A. Hurvitz Joyce O’Shaughnessy Ginny Mason Denise A. Yardley Mohammad Jahanzeb Adam Brufsky Hope S. Rugo Sandra M. Swain Peter A. Kaufman Debu Tripathy Laura Chu Haocheng Li Vincent Antao Melody Cobleigh

View at Publisher

Ask AI

Bookmark

Share

Abstract

Despite advances in HER2-targeted treatments, patients with CNS metastasis continue to have a poor prognosis and impaired quality of life. Observation of CNS metastasis appears to influence HER2-targeted treatment choice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hurvitz et al. (2018) studied this question.

synapsesocial.com/papers/69dd67f87dbdc4ad1440c8c1 https://doi.org/10.1158/1078-0432.ccr-18-2366

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)Cohort Study · 2006 · 413 citations
2Metastatic Behavior of Breast Cancer SubtypesCohort Study · 2010 · 2,257 citations
3Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHERRegistry Study · 2011 · 386 citations
4Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancerPrognostic Study · 2010 · 131 citations
5Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab eraCohort Study · 2013 · 128 citations

More related papers

Metastatic breast cancer subtypes and central nervous system metastases2014
Breast cancer brain metastases: the last frontier2015
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer2011

More from Clinical Cancer Research

Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trialWed,
DuoBody®-FAPαxDR4 is a novel DR4 agonist that induces potent antitumor activity through FAPα-dependent, DR4-transactivation-mediated apoptosisWed,